Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Informatics
AI drug discovery company Evogene partners with Google Cloud
by Aayushi Pratap
November 8, 2024
| A version of this story appeared in
Volume 102, Issue 35
The Israeli venture hub AION Labs has launched ProPhet, a startup intended to use artificial intelligence to identify small molecules for drug discovery. In a statement, ProPhet CEO Tom Shani says the firm’s technology allows it to screen small-molecule libraries against proteins in various possible conformational states. Meanwhile, the Israeli computational biology company Evogene has partnered with Google Cloud to ramp up the computational power needed for its AI model for designing small-molecule drugs.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X